Trimel Pharma gains on phase 2 study results for drug to aid female orgasms

May 28, 2014 12:23 PM

17 0

Trimel Pharmaceuticals (TSE:TRL) shares were on the rise Wednesday after reporting positive results from a phase II clinical trial of Tefina, a testtosterone nasal gel designed to treat female orgasmic disorder.

The disorder, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasm, often causing significant distress.

Also read: IQ Scores Are Falling Due to Environmental Factors, Study Finds

Read more

To category page